Edward White
Stock Analyst at HC Wainwright & Co.
(1.84)
# 3,055
Out of 4,847 analysts
384
Total ratings
26.46%
Success rate
-7.75%
Average return
Main Sectors:
Stocks Rated by Edward White
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Reiterates: Buy | $33 | $8.97 | +267.89% | 24 | Apr 16, 2025 | |
| VALN Valneva SE | Reiterates: Buy | $17 | $6.20 | +174.19% | 41 | Apr 15, 2025 | |
| INZY Inozyme Pharma | Reiterates: Buy | $16 | $3.98 | +302.01% | 14 | Apr 10, 2025 | |
| NYXH Nyxoah | Reiterates: Buy | $15 | $7.83 | +91.69% | 15 | Apr 8, 2025 | |
| SABS SAB Biotherapeutics | Reiterates: Buy | $6 | $1.86 | +222.58% | 15 | Apr 1, 2025 | |
| CRIS Curis | Maintains: Buy | $20 → $16 | $2.30 | +595.65% | 18 | Mar 31, 2025 | |
| IKT Inhibikase Therapeutics | Reiterates: Neutral | n/a | $2.05 | - | 11 | Mar 28, 2025 | |
| SNSE Sensei Biotherapeutics | Reiterates: Buy | $4 | $0.34 | +1,083.08% | 6 | Mar 28, 2025 | |
| SXTP 60 Degrees Pharmaceuticals | Reiterates: Neutral | n/a | $2.91 | - | 11 | Mar 28, 2025 | |
| ARTV Artiva Biotherapeutics | Reiterates: Buy | $20 | $1.93 | +936.27% | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.31 | - | 12 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $2.41 | +563.90% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $25 | $6.35 | +293.70% | 6 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $0.88 | +809.09% | 25 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $4.36 | - | 2 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.78 | - | 23 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $55 | $36.41 | +51.06% | 31 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 | $11.20 | +355.56% | 29 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $3.33 | +110.21% | 20 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $56 | $4.25 | +1,217.65% | 28 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $31 | $10.01 | +209.69% | 21 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.21 | - | 12 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.09 | - | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $0.35 | +7,927.52% | 3 | Aug 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $30 | $21.64 | +38.63% | 5 | Aug 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 | $1.36 | +782.35% | 2 | Mar 6, 2018 | |
Cullinan Therapeutics
Apr 16, 2025
Reiterates: Buy
Price Target: $33
Current: $8.97
Upside: +267.89%
Valneva SE
Apr 15, 2025
Reiterates: Buy
Price Target: $17
Current: $6.20
Upside: +174.19%
Inozyme Pharma
Apr 10, 2025
Reiterates: Buy
Price Target: $16
Current: $3.98
Upside: +302.01%
Nyxoah
Apr 8, 2025
Reiterates: Buy
Price Target: $15
Current: $7.83
Upside: +91.69%
SAB Biotherapeutics
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.86
Upside: +222.58%
Curis
Mar 31, 2025
Maintains: Buy
Price Target: $20 → $16
Current: $2.30
Upside: +595.65%
Inhibikase Therapeutics
Mar 28, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.05
Upside: -
Sensei Biotherapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: $4
Current: $0.34
Upside: +1,083.08%
60 Degrees Pharmaceuticals
Mar 28, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.91
Upside: -
Artiva Biotherapeutics
Mar 26, 2025
Reiterates: Buy
Price Target: $20
Current: $1.93
Upside: +936.27%
Mar 25, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.31
Upside: -
Mar 25, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $2.41
Upside: +563.90%
Mar 25, 2025
Maintains: Buy
Price Target: $22 → $25
Current: $6.35
Upside: +293.70%
Mar 21, 2025
Reiterates: Buy
Price Target: $8
Current: $0.88
Upside: +809.09%
Mar 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $4.36
Upside: -
Mar 7, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.78
Upside: -
Mar 4, 2025
Reiterates: Buy
Price Target: $55
Current: $36.41
Upside: +51.06%
Mar 4, 2025
Reiterates: Buy
Price Target: $51
Current: $11.20
Upside: +355.56%
Feb 28, 2025
Reiterates: Buy
Price Target: $7
Current: $3.33
Upside: +110.21%
Feb 26, 2025
Maintains: Buy
Price Target: $7 → $56
Current: $4.25
Upside: +1,217.65%
Feb 21, 2025
Reiterates: Buy
Price Target: $31
Current: $10.01
Upside: +209.69%
Jun 4, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.21
Upside: -
Nov 8, 2021
Initiates: Neutral
Price Target: n/a
Current: $1.09
Upside: -
Aug 30, 2021
Initiates: Buy
Price Target: $28
Current: $0.35
Upside: +7,927.52%
Aug 11, 2021
Maintains: Buy
Price Target: $34 → $30
Current: $21.64
Upside: +38.63%
Mar 6, 2018
Downgrades: Neutral
Price Target: $12
Current: $1.36
Upside: +782.35%